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Background: Hospitalization attributed to severe exacerbations is the major cost driver of
Chronic Obstructive Pulmonary Disease (COPD). Given that in Greece no previous studies have
addressed the economic burden of COPD, the aim of the study was to examine the hospitali-
zation cost of COPD patients with severe exacerbations in the region of Thrace.
Methods: Sample consisted of 142 COPD patients with severe exacerbations who were
admitted to the pneumonology department of the University Teaching Hospital of Alexandrou-
polis (UTHA) in 2006 and 2007. Data collection was performed retrospectively and resource
utilization was derived from patients’ files. General Linear Model univariate analysis was
applied in order to test the influence of disease severity on costs.
Results: Mean actual cost per severe exacerbation was V1711; the amount of V621 is reim-
bursed by social security funds. Price discrepancies are observed between the actual and
the nominal cost per patient in all disease stage categories. Mean hospitalization cost per
COPD patient increases slightly with the severity of the disease. However, in the very severe
stage it greatly increases mainly due to Intensive Care Unit (ICU) admission. In multivariate
analysis the length of stay and the stage of the disease were both related to significantlysting; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; GOLD, global
onary disease; HRQoL, health related quality of life; LoS, length of stay; ICU, intensive care unit; NHS,
eviation; CI, confidence intervals; Q1, quarter 1; Q3, quarter 3; UTHA, University Teaching Hospital of
r. 21, 153 51 Pallini, Athens, Greece. Tel.: þ30 6955460765.
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6, Greece.
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The cost of COPD exacerbations in Greece 403increased costs, while the existence of co-morbidities exhibited marginal significant relation to
increased cost.
Conclusions: The cost estimation of severe exacerbations is important as it could trigger
further research and also provide the opportunity of creating national epidemiological and
economic data. Such data could contribute to the estimation of the total economic and soci-
etal burden of COPD in the country.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a leading
cause of morbidity and mortality with a substantial and
increasing societal burden on the developed world.1e6 The
World Health Organisation (WHO) predicts that COPD will
become the third leading cause of death by 2030 on a world
scale.7 Although the prevalence of COPD varies from
country to country, population-based studies have shown
an overall prevalence ranging from 4 to 10% in the general
adult population.8e11 The effects of COPD on morbidity and
mortality both in terms of life-years lost and disability-
adjusted life-years (DALYs) are important when considering
the overall disease burden.
The direct and indirect costs of COPD vary considerably
among countries, however, they appear to be greater in the
USA than those in Europe and in Canada.12 Direct cost
accounted for 73% of the total cost of COPD in the USA.13
Furthermore, the loss of productivity in patients of
working age is reported to range from 41% in Spain to 82% in
the USA, bringing with it a significant societal strain.12
Patients suffering from COPD frequently develop exac-
erbations which lead to major clinical implications and
healthcare utilisation. Severe exacerbations that require
hospitalization are the major cost drivers in COPD and are
frequently associated with increased mortality and
impaired health related quality of life (HRQoL).14e16 Recent
studies indicate that hospitalization costs represent
approximately 35e54% of the total COPD treatment
expenditures.17e23 For this reason, prevention and treat-
ment of exacerbations is an important objective of COPD
maintenance therapy.
The economic and societal burden of COPD has never
been studied in Greece. However, the prevalence of COPD
in Greece is estimated to be 8.4% of the overall population,
6% in Athens, 15.1% in men living in rural areas, up to 17.1%
in the older population.6,24 COPD is found in 10.4% of
people with smoking history, twice the rate of non-smokers
which is 4.8%6 while two thirds of those who suffer from
COPD remain undiagnosed.24
Theaimof this studywas toestimatehospitalizationcost of
COPD patients with severe exacerbations who had been
admitted to the University Teaching Hospital of Alexan-
droupolis (UTHA) and to subsequently investigate any
discrepancies between actual hospitalization cost and reim-
bursement from social insurance funds. The National Health
System (NHS) perspective has been considered in the analysis.
By identifying the cost of COPD exacerbation both healthcare
professionals andpolicy-makerswill bebetter informedwhich
may, in turn, contribute to public health policy interventionsAdditionally, these studies will help to develop a framework
for creating economic and epidemiological databases in
countries where there is limited data available.
Materials and methods
The study sample consisted of 142 COPD patients with
severe exacerbations admitted to the UTHA’s Department
of Pneumonology in 2006 and 2007. Data was collected
retrospectively and patients eligible for inclusion were
those who had been diagnosed with COPD at least 6 months
prior to their visits to the UTHA Emergency Department and
whose spirometric data (pre and post broncodilation) was
available. Selected patients were categorized into four
stages disease severity, based on their condition prior to
exacerbation. Diagnosis, exacerbation and patient catego-
rization were based on the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria.25 COPD exacer-
bation is defined as “an event in the natural course of the
disease characterized by a change in the patient’s baseline
dyspnea, cough and/or sputum, which is beyond normal
day-to-day variations, is acute in onset and may warrant
a change in medication in a patient with underlying COPD”.
Patients with severe exacerbations were considered those
requiring hospitalization, according to GOLD indications for
hospital admissions for exacerbations of COPD.25
A total number of 208 patientswere admitted to theUTHA
with COPD severe exacerbations in 2006 and 2007, 88 and 120
patients respectively. 142 patients met the inclusion criteria
and also submitted consent forms while 66 patients were
excluded fromtheanalysis.Of thoseexcluded, 41hadnopre-
or post-bronchodilation spirometry, 6 had experiencedmore
than one severe exacerbation (only the first exacerbation
was included in the analysis) and 19 patients declined to
participate. The study was approved by the hospital’s Ethics
Committee.
UTHA, the leading hospital in the Thrace region, is
affiliated with Democritus University of Thrace and located
in Alexandroupolis, the region’s largest city. Thrace’s
economy is primarily dependent on agriculture. The deci-
sion to conduct the analysis in this particular region was
made to ensure that the results can be representative to
the rural areas with the highest prevalence rates of COPD,
and cannot be generalised to the entire population of the
country. Healthcare delivery and funding mechanisms are
uniform across Greece; specifically, health insurance is
compulsory and universal while free access to healthcare
is provided by all NHS hospitals. Primary healthcare is
provided by the Social Security Funds polyclinics, outpa-
tient units at NHS hospitals and health centres. Hospital
404 M. Geitona et al.care is mostly provided by the NHS hospitals and is financed
by Social Insurance Funds.
Cost analysis was based on the estimation of patients’
actual and nominal costs. Actual cost refers to the resources
patients consumed during their hospital stay. Nominal cost
refers to a fixed amount for each day of hospitalization
reimbursed by the social security funds (per diem payment)
in all NHS hospitals, irrespective of patients’ diagnosis,
disease severity and resource consumption. The analysis was
based on the estimation of the COPD patients’ hospitaliza-
tion cost adopting the perspective of the National Health
System (NHS). Cost estimates of hospitalization was con-
ducted using the Activity Based Costing (ABC) bottom-up
approach, which identifies all resources directly employed
for the provision of healthcare.26 This microeconomic anal-
ysis was selected to ensure consistency and transparency of
results, as no national cost data was available.
Clinical and epidemiological data was collected using
patient records; while economic data was obtained from
the hospital’s administrative and finance departments.
Utilization data consisted of a) resource consumption
including supplies, medication, laboratory and imaging
testing b) operational and other overhead costs and c)
personnel costs. Capital asset depreciation was also
included in the analysis obtained from the hospital balance
sheet and allocated by the total number of admitted
patients to the UTHA.
The estimated actual cost per patient was compared to
the amount reimbursed from social security funds based on
the per diem payment for inpatient care. The cost per
patient in the intensive care unit (ICU) was based on pub-
lished data and it inflated to the 2006 Euro rate.27
Pharmaceutical cost was based on national pharmaceu-
tical formulary prices and the cost of diagnostic tests was
estimated using official NHS prices. The per diem payment
was obtained from the Official Government Gazette and
estimated at the rate of V94 per inpatient day and V188 for
ICU day (Government Gazette 99B/10-2-98).
All data associated with personnel cost was obtained
using budgetary control statements provided by the hospi-
tal’s Finance Department. Personnel cost includes salaries
for full-time medical and nursing staff employed by the
Department of Pneumonology, averaged by the number of
patients treated annually in the department. Other
personnel costs associated with paramedical, administra-
tive and technical staff that provide services for the overall
operation of the hospital, were allocated by the number of
patients admitted to the hospital on an annual basis. The
cost of consumables was reported on a per patient basis
and was obtained by the hospital’s Supplies Department.
Operational and general overhead costs including elec-
tricity, water, heating, telephone and other utilities were
obtained from budget control statements representing the
total overhead hospital expenses. The allocation of over-
head expenses was based on the space occupied and used
by the Pneumonology Department (in square meters) over
the total area of the hospital. The Pneumonology Depart-
ment’s overhead costs were then averaged over all patients
admitted to the department on an annual basis. The cost of
diagnostic testing, medication, oxygen therapy and any
other specialized medical examinations was reported on
a per-case basis.Statistical analysis
Univariate analyseswereperformed in order to determine the
relationbetweenage, gender, smokingpatterns, timeof year,
Length of Stay (LoS), disease severity and co-morbidity and
the outcome (cost of hospitalization). Co-morbidity was
defined as the presence of at least one of the following
conditions: respiratory infection and/or fever (25/39),
cardiovascular disease under medication (12/39) (i.e. heart
failure, hypertension, stroke) and kidney failure (2/39). Using
the univariate approach, hospitalization costs were analysed
by i) all patients except eight admitted to the ICU ii) all
patients excluding ICU costs and iii) all patients including ICU
costs, in order to identify each relevant variable. The only
variable that exhibited a significant relation was that of LoS.
Season and disease stage showed weak but not significant
relations (pw0.2). In the finalmultivariatemodeling, General
Linear Model (GLM) analysis was applied; the first two models
(i and ii) fitted greatly to GLM assumptions while the third did
not fit so well as the costs of ICU admission caused a right
skewing in the data. ICU costs (originated from 8 patients,
all categorized in the very severe stage of COPD) were
very strongly dependant on LoS and showed no significant
relation to time of year, co-morbidity and smoking pattern
(pZ 0.10e0.20). Based on the aforementioned approach and
findings, and the modest sample size, the parametric
approach was maintained as it is proven to fit well and illus-
trates the underlying causes of variance and skewing in our
data. Data analyses were conducted using SPSS for Windows
16.1.0 statistical package.
A bootstrap simulation of 1.000 iterations was run in
Microsoft Excel to illustrate variations in cost estimates for
all COPD disease stage categories. In addition, a sensitivity
analysis was performed using the median in order to
examine the degree of arithmetic mean unreliability and
standard deviation as well as to serve as a guide for the
degree of skew. Furthermore, a sensitivity analysis was
performed in order to test the effect of varying assump-
tions by reducing the major cost drivers, personnel and
consumables costs by 20%.
Results
The characteristics of the sample, classified according to
disease severity, are presented in Table 1. The majority of
COPD patients were men (93%), farmers (62%) and smokers
(60.6%) with an average of 79 pack-years. Only 8.4% of the
sample had never smoked in the past. It is also observed
that the length of stay (LoS) does not deviate much
according to the COPD stage. Nine patients in stage IV were
admitted to the ICU, resulting in the prolongation of their
length of stay.
The cost analysis according to stage of disease severity
and the various cost drivers is presented in Table 2.
Personnel cost is the leading cost driver representing 54.5%
of the total hospitalization cost, followed by the cost
of intensive care at 17.3% based on the care of only
9 patients. The cost of consumables is relatively high rep-
resenting 15.4% of the total hospitalization cost. Laboratory
and pharmaceutical costs account for 7% and 4% of total
cost respectively. Pharmaceutical cost distribution was
Table 1 Patients’ characteristics (nZ 142).
Patients’ characteristics Mild COPD
(Stage I)
nZ 3
Moderate COPD
(Stage II)
nZ 38
Severe COPD
(Stage III)
nZ 66
Very severe COPD
(Stage IV)
nZ 35
All patients
nZ 142
Men (n, (%)) 3 (100) 33 (87) 62 (94) 34 (97) 132 (93)
Age (in years, mean, (sd)) 72.7 (0.6) 70.7 (11.3) 70.7 (7.9) 72.8 (5.7) 71.2 (8.4)
Farmers (n, (%)) 2 (66.6) 13 (34.2) 48 (72.7) 25 (71.4) 88 (61.9)
Current smoker (n, (%)) 3 (100) 19 (50) 38 (57.6) 26 (74.3) 86 (60.6)
Pack-Years (mean, (sd)) 65 (50.7) 67.3 (22.8) 70.9 (29.4) 100.8 (29) 78.6 (31.9)
Ex-smoker (n, (%)) e 14 (36.8) 22 (33.3) 8 (22.9) 44 (31)
Pack-years (mean, (sd)) e 103.6 (101.2) 71.4 (17.1) 60.9 (32.5) 79.7 (60.8)
Never smoker (n, (%)) e 5 (13.2) 6 (9.1) 1 (2.9) 12 (8.4)
FEV1% (mean, (sd)) 83 (5.2) 62.7 (11.3) 52.3 (16.5) 38.8 (11.7) 52.4 (16.9)
LoS (in days, mean, (sd)) 6 (3) 5.4 (5.2) 6.5 (3.9) 5.5 (3) 6 (4.1)
ICU LoS (in days, mean, (sd)) e e e 6.9 (1.9) 6.9 (1.9)
Abbreviations: LoS: Length of Stay, COPD: Chronic Obstructive Pulmonary Disease, ICU: Intensive Care Unit, SD: Standard Deviation.
The cost of COPD exacerbations in Greece 405based on 67% for antibiotics, 16% oral corticosteroids and
13% Short Acting Bronchodilator Agent (SABAs) and only 3%
for other pharmaceuticals, mainly for gastro protection.
In Table 3 the estimated mean actual and nominal cost
per patient according to the stage of disease severity is
presented. Hospitalization cost per COPD patient increases
slightly with the severity of the disease and varies consid-
erably in the very severe stage given the patient’s admis-
sion to the ICU. Additionally, a discrepancy is observed
between the actual and the nominal cost per patient in all
disease stage categories. This variation ranges from V793
to V1.800 depending on the disease stage; the greatest
difference is seen in patients at the very severe stage
where the actual cost was three times higher than the
amount reimbursed by Greek social security funds.
Statistical analysis
According to the general linear model presented in Table 4,
total costs have a skewed distribution which is indicated by
the relatively low median values in the severity groups
compared to the average. The very severe COPD category is
the most costly category due to the high costs of ICU care.
Despite cost increases related to women, older age, present
smoking habits and time of year (seasons), none of these
particular variables reached statistical significance. The
length of stay and the existence of co-morbid conditions
were, however, related to increased cost. A log trans-
formation of the total costs did not improve the model fit, as
judging from the residuals.Sensitivity analysis
The median value was used to examine cost variations per
COPD stage. According to Table 5, variations were small in
the three COPD stages, excluding stage IV, to safely
conclude that the results were reliable. Bootstrap simula-
tion was performed with 1000 iterations to illustrate vari-
ations in estimates from the arithmetic mean. The results
of the simulation did not deviate enough from the original
analysis. The bootstrap simulation led to the observation ofa slight difference in the narrowing of the confidence
intervals due to a larger sample size. Additionally, results of
the sensitivity analysis, revealed a 3% reduction in the
mean cost per patient in the case of consumables and
almost an 11% reduction in personnel costs.
Discussion
This bottom-up micro-costing study highlighted the discrep-
ancies between actual and nominal cost per patient with
severe exacerbation in all disease stage categories. Mean
hospitalization cost per COPD patient increases slightly with
the severity of the disease and it varies considerably in the
very severe stage due to the patient’s admission to the ICU.
Personnel costs are shown to be the major cost driver, rep-
resenting almost 55% of the total cost of hospitalization.
The mean actual cost per patient with severe exacerba-
tion wasV1.711; almost three times the amount reimbursed
by social security funds (V621). This finding appears to be
very important as the per diem payment, which reflects the
nominal cost, does not, in fact, cover the patient’s actual
cost of hospitalization. The continuation of this situation
over years has resulted in deficits across all NHS hospital
budgets as the amount reimbursed by social funds remains
common to all NHS hospitals. Therefore, hospital deficits
must be covered by state funding thereby creating an
ongoing burden to the national economy. Additionally, there
are further implications whenever any economic evaluation
is undertaken in Greece, whether for COPD or any other
diseases. Given the lack of actual hospitalization cost,
economic evaluation studies take nominal cost data into
account which, in turn, bring about the question in terms of
accuracy of results and comparability with international
data.
Themajority of our results are consistent with those found
in international literature. The multivariate analysis showed
that LoS and disease stage were significantly related to
increased costs while the existence of co-morbidities exhibi-
ted a marginally significant relation to increased cost. This
finding is in keeping with studies performed in France, the
Netherlands and Belgium28e30 indicating that direct costs
increasewith disease severity. In a study conducted in 2000 in
T
a
b
le
2
T
o
ta
l
co
st
s
b
re
a
kd
o
w
n
b
y
C
O
P
D
p
a
ti
e
n
ts
’
cl
a
ss
ifi
ca
ti
o
n
in
E
u
ro
s.
C
O
P
D
St
a
ge
N
u
m
b
e
r
o
f
p
a
ti
e
n
ts
(%
)
P
h
a
rm
a
ce
u
ti
ca
l
co
st
La
b
o
ra
to
ry
co
st
C
o
n
su
m
a
b
le
s
co
st
T
o
ta
l
a
n
ci
ll
a
ry
co
st
a
C
o
st
o
f
p
e
rs
o
n
n
e
l
O
ve
rh
e
a
d
co
st
In
te
n
si
ve
ca
re
C
o
st
T
o
ta
l
C
o
st
M
e
a
n
co
st
p
e
r
p
a
ti
e
n
t
St
a
ge
I
3
(2
)
65
34
0
79
2
1.
19
7
2.
79
9
75
0
4.
07
1
1
.3
5
7
St
a
ge
II
38
(2
7)
2.
75
9
4.
17
2
10
.0
32
16
.9
63
35
.4
54
95
0
0
53
.3
67
1
.4
0
4
St
a
ge
II
I
66
(4
6)
5.
02
0
8.
34
5
17
.4
24
30
.7
89
61
.5
78
1.
65
0
0
94
.0
17
1
.4
2
5
St
a
ge
IV
35
(2
5)
2.
45
4
4.
19
7
9.
24
0
15
.8
91
32
.6
55
87
5
42
.0
68
91
.4
89
2
.6
1
4
T
o
ta
l
14
2
(1
00
)
10
.2
98
17
.0
54
37
.4
88
64
.8
40
13
2.
48
6
3.
55
0
42
.0
68
24
2.
94
4
1
.7
1
1
T
h
e
b
o
ld
va
lu
e
s
re
p
re
se
n
t
th
e
m
e
a
n
co
st
p
e
r
C
O
P
D
st
a
ge
p
a
ti
e
n
t.
a
T
o
ta
l
A
n
ci
ll
ar
y
co
st
in
cl
u
d
e
s
e
xp
e
n
se
s
fo
r
p
h
a
rm
a
ce
u
ti
ca
l,
la
b
o
ra
to
ry
a
n
d
co
n
su
m
ab
le
s.
406 M. Geitona et al.the UK, the cost per COPDpatientwas estimated atV1270 per
patient.22 In 2002 study carried out in Sweden,31 focusing on
the direct cost of exacerbation, substantial cost differentia-
tions among the disease severity stages were observed, which
are not found in the present study. Additionally, the very
severe exacerbation cost found in the Swedish study appears
to be approximately the same as that found in the present
study; V2325 in Sweden and V2614 in Greece. By converting
the aforementioned costs intoUS dollars using Gross Domestic
Product (GDP) Purchasing Power Parities (PPPs) (2006
values),32 and in order to beable to provide an equivalent cost
of severe exacerbations between the two countries, great
variations are observed. Specifically, the costs are $3738 and
$2463 in Greece and in Sweden respectively. Several studies
also report that the cost of pharmaceuticals is a relatively
minor driver of hospitalization cost.18,19,29
A key result of the present study which should be noted
is the high rate of tobacco consumption (80 pack-years).
This finding is in accordance with the OECD data reporting
Greece with the highest percentage of adult tobacco use
among OECD countries.33,34 It is worth noting that an
epidemiological study on smoking, carried out in the
general population of Northern Greece,35 found that men
aged between 61 and 80 years had a smoking history of 55.5
(30.5) pack-years and considering that this study focused
on a disease specific population, our findings of 80 pack-
years is not surprising.
It is worth stating that there are differences in COPD
cost estimates among various international stud-
ies.20,2830,36 Given the methodological issues raised in
cost-of-illness studies and the question of incomparability
among international cost estimates, the aforementioned
differences appear to depend on the use of different
research hypothesis and methodologies, sample selection
and size, data sources and organizational structure of the
healthcare systems mainly with regard to healthcare
delivery and financing. Great cost variations are observed
in an international survey investigating the COPD cost of
treatment, although data collection was based on
a standardised micro-costing methodology.22,37 Specifi-
cally, in 2000 the annual direct cost of treatment was $522
in France, $1258 in Canada, $3196 in Spain and $4119 in
the USA.12 Typically, cross-country cost-of-illness
comparisons are made at the macro-level and based on
standardised data available from a variety of international
databases. However, the macro-costing perspective may
not always analyse the differences in resource consump-
tion and related costs.38 Using cost data at the micro-level
for an individual patient is more useful in cases where
data is usually not available in a standardised form, even
though it might result to cost underestimation.27 The fact
that micro-costing data analysis was performed in this
study, may contribute to the standardisation of hospital
data, the enhancement of cost comparability among
hospitals and consequently, increased efficiency of NHS
hospitals.30,37,39 It is important to note that the above
mentioned studies report inpatient hospitalization as the
most important key-driver.
The present study has some limitations that may merit
consideration such as the fact that the results generally
apply to COPD patients living in rural areas. However, the
decision to study the specific university hospital was based
Table 3 Actual versus nominal cost per COPD patient, in V.
COPD Stage Number of patients Mean actual cost per patient (95% CI) Nominal cost per patienta
Stage I 3 1.357 (1.231e1.482) 564
Stage II 38 1.404 (1.369e1.440) 505
Stage III 66 1.425 (1.398e1.454) 602
Stage IV 35 2.614 (1.816e3.412) 814
All 142 1.711 (1.503e1.920) 621
a Nominal cost is based on fixed prices.
The cost of COPD exacerbations in Greece 407on the lack of available national or local COPD registries
and the goal of establishing a pilot project that will gather
preliminary epidemiological, clinical and economic data
from the specific region. The cost of personnel divided
proportionally by the number of patients, regardless of
their length of stay or disease severity, also constitutes
another limitation. The lack of analytical NHS hospital
registries regarding patient classification per disease
severity as well as personnel time dedicated to each
patient, did not allow for such estimation. The classifica-
tion of patients related to resource consumption carried
out in the current analysis, may, however provide impor-
tant and useful information to policy-makers in order to
establish per-case payment rates as well as for the use of
hospital benchmarking. Finally, estimation of the ICU cost
was not recorded on a per patient basis but was based on
published data.27 In addition, indirect cost was not included
in the analysis.Table 4 General linear model of total cost due to hospitalizati
Coefficient 9
L
Intercept 1534.98 
Season (admission)
Spring 224.26 
Summer 220 
Autumn 206.06 
Winter 0
Smoking
Never 228.22 
Ex 199.1 
Current 0
Disease stage
Mild (Stage I) 1330 
Moderate (Stage II) 958.6 
Severe (Stage III) 1020.35 
Very severe (Stage IV) 0
Gender
Male 70.2 
Female 0
Age 9.43 
Length of stay (day) 98.84
Co-morbidity
No 392.54 
Yes 0The need for scientific evidence in treating the specific
chronic condition should be strongly supported particularly in
Greece as it has one of the highest prevalence rates of heavy
smokers, undiagnosed and undertreated patients.6,24,34,35,40
Consequently, carrying out cost analysis studies is key to
identifying major cost drivers of COPD treatment and allo-
cating rationally health resources. Moreover, results of
economic evaluation studies would more accurately reflect
reality and would be comparable to international literature.
In an era of economic recession, healthcare profes-
sionals must take the results of economic evaluation studies
under careful consideration in their decision making
processes so as to improve health outcomes and minimize
cost. Further epidemiological and economic research on
COPD will undoubtedly contribute to the creation of
national registries. As a result, this will contribute to
establishing a more accurate picture of the disease’s total
implications for the country.on of COPD exacerbations.
5% Confidence Interval P value
ower Bound Upper Bound
565.25 3635.21 0.151
255.33 703.85 0.357
343.11 783.1 0.441
743.95 331.83 0.45
912.57 456.13 0.511
611.77 213.57 0.342
2665.69 5.68 0.051
1493.68 423.52 0.001
1490.85 549.85 <10e3
822.46 682.06 0.854
13.64 32.5 0.42
54.99 142.7 <10e3
821.52 36.44 0.073
Table 5 Sensitivity Analysis Results.
COPD
Stage
Median cost
per patient (V)
Q1 (V) Q3 (V) Bootstrapp simulation
mean cost (V) (95% CIs)
Mean cost per
patient (V)a
Mean cost per
patient (V)b
Stage I 1369 1335 1384.5 1355 (1301e1400) 1170.2 1304
Stage II 1406.5 1318 1456.25 1405 (1372e1440) 1217.8 1351.6
Stage III 1417 1330.5 1509.75 1425 (1398e1454) 1237.9 1371.7
Stage IV 2622 1873 3459 2603 (1925e3394) 2427.4 2561.2
Abbreviations: Q1: Quarter 1, Q3: Quarter 3, CIs: Confidence Intervals.
a Mean cost per patient with 20% personnel cost reduction.
b Mean cost per patient with 20% consumables cost reduction.
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